)
Longeveron (LGVN) investor relations material
Longeveron Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Laromestrocel remains the lead investigational therapy across four potential indications; strategic and financing alternatives, including a potential business combination, are under review with Lucid Capital Markets as advisor.
ELPIS II missed its primary HLHS efficacy endpoint; an updated analysis found fewer adjudicated events and a statistically significant MACE difference, and an FDA meeting was requested to discuss next steps.
Financial highlights
Q3 2026 revenue was $115K vs. $137K YoY; gross profit was $71K vs. $125K, with lower contract manufacturing revenue contributing to the decline.
Q3 operating loss was $7.2M vs. $7.3M; net loss was $6.1M vs. $7.2M, reflecting $1.0M of XPRIZE Healthspan award income and lower G&A expense.
9M 2026 revenue was $800K vs. $834K; operating loss was $18.1M vs. $17.9M and net loss was $16.9M vs. $17.3M.
9M operating cash use was $12.7M; financing provided $15.5M, lifting cash by $2.6M to $7.2M at September 30, 2026.
Outlook and guidance
Cash and cash equivalents of $7.2M were expected to fund operations into Q1 2027 under current plans and cash-conservation measures; additional capital will be needed to advance development.
Strategic alternatives may include a partnership or investment, additional financing, a sale or merger, or a business combination; no definitive timeline or assured outcome was established.
HLHS next steps depend on FDA review of ELPIS II; proposed AD Phase 2/3 and pediatric DCM trial plans depend on partnerships, funding and strategic review.
Forecasts show insufficient cash to meet minimum expenditure commitments for one year from financial-statement issuance; substantial doubt exists about the ability to continue as a going concern.
- ELPIS II topline data are anticipated in Q3 2026 as laromestrocel advances across four indications.LGVN
Investor presentation - ELPIS I showed 100% five-year transplant-free survival in treated HLHS patients.LGVN
Investor presentation - Laromestrocel advances across three indications, with pivotal trials planned or underway.LGVN
Investor presentation - Pivotal HLHS and planned Alzheimer's and PDCM trials anchor laromestrocel's pipeline.LGVN
Investor presentation - Laromestrocel spans three indications, with ELPIS II pivotal if positive.LGVN
Investor presentation - Lomecel-B advances across three indications, with encouraging HLHS, AD and frailty data.LGVN
Investor presentation - Laromestrocel's late-stage data and PRV eligibility position it for major value inflection.LGVN
Investor presentation - Q2 2026 net loss rose to $6.1M as cash runway extends into Q4 2026 ahead of key trial results.LGVN
Q2 2026 - All proposals, including director elections and share amendments, were approved by majority vote.LGVN
AGM 2026
)
)
)
)
)
)
)
)